Vireo Growth (VREOF) Current Assets (2020 - 2026)
Vireo Growth (VREOF) reported Current Assets of $258.3 million for Q1 2026, up 13.07% on a YoY basis from $228.4 million in Q1 2025, and down 15.34% sequentially from $305.1 million in Q4 2025.
Vireo Growth (VREOF) Current Assets (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Current Assets data on file, last reported at $258.3 million in Q1 2026.
- For the quarter ending Q1 2026, Current Assets rose 13.07% year-over-year to $258.3 million; the trailing twelve-month figure through Mar 2026 stood at $258.3 million (up 13.07% YoY), and the FY2025 full-year result was $305.1 million, up 32.44% from the prior year.
- Current Assets declined to $258.3 million in Q1 2026, from $305.1 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $312.8 million in Q2 2025 to a low of $38.8 million in Q1 2022.
- A 5-year average of $164.4 million and a median of $147.2 million in 2024 frame the typical range for Current Assets.
- Across the five-year window, Current Assets sank 33.89% in 2022 and soared 218.55% in 2023, its largest moves.
- Tracing VREOF's Current Assets over 5 years: stood at $46.7 million in 2022, then soared by 218.55% to $148.9 million in 2023, then surged by 54.77% to $230.4 million in 2024, then jumped by 32.44% to $305.1 million in 2025, then slipped by 15.34% to $258.3 million in 2026.
- Business Quant data shows VREOF's Current Assets at $258.3 million in Q1 2026, $305.1 million in Q4 2025, and $308.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.05 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.71 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 6.47 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 19.71 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 2.87 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 53.60 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 10.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.44 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.58 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 258.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 258.30 Mn |
| Dec 31, 2025 | 305.10 Mn |
| Sep 30, 2025 | 307.96 Mn |
| Jun 30, 2025 | 312.79 Mn |
| Mar 31, 2025 | 228.43 Mn |
| Dec 31, 2024 | 230.37 Mn |
| Sep 30, 2024 | 143.96 Mn |
| Jun 30, 2024 | 148.63 Mn |
| Mar 31, 2024 | 147.18 Mn |
| Dec 31, 2023 | 148.85 Mn |
| Sep 30, 2023 | 135.11 Mn |
| Jun 30, 2023 | 126.37 Mn |
| Mar 31, 2023 | 115.56 Mn |
| Dec 31, 2022 | 46.73 Mn |
| Sep 30, 2022 | 53.86 Mn |
| Jun 30, 2022 | 46.39 Mn |
| Mar 31, 2022 | 38.75 Mn |
| Dec 31, 2021 | 41.64 Mn |
| Sep 30, 2021 | 44.75 Mn |
| Jun 30, 2021 | 41.96 Mn |